Anthem Biosciences Share Price Target 2025: Anthem Biosciences, a Bengaluru-based Contract Research, Development, and Manufacturing Organization (CRDMO), made waves with its recent IPO, listing on the BSE and NSE on July 21, 2025. As a company specializing in drug discovery, development, and manufacturing, it’s caught the eye of investors looking for long-term growth in the pharmaceutical and biotech sectors. But what can we expect from Anthem Biosciences’ share price in 2025? Let’s dive into the factors influencing its potential, its recent performance, and what analysts are saying about its future.
Table of Contents
A Strong IPO Debut Sets the Stage
Anthem Biosciences’ IPO was a resounding success, raising ₹3,395 crore through an offer-for-sale (OFS) of 5.96 crore equity shares priced at ₹570 each. The issue was oversubscribed 67.42 times, driven by strong demand from qualified institutional buyers (QIBs) who subscribed 192.80 times their allocated portion. Retail investors and non-institutional investors also showed enthusiasm, subscribing 5.98 and 44.70 times, respectively.
The grey market premium (GMP) before listing hovered around ₹179, suggesting an estimated listing price of ₹749, a 31.4% premium over the issue price. On listing day, the stock opened at ₹723 on BSE’s pre-open session, reflecting strong market confidence. This robust debut indicates investor optimism about Anthem’s growth potential, but sustaining this momentum will depend on its operational performance and market dynamics.
Financial Performance Fuels Optimism
Anthem Biosciences has shown impressive financial growth, which underpins its appeal to investors. In FY25, the company reported a revenue of ₹1,844.6 crore, a 30% increase from ₹1,419.37 crore in FY24. Its profit after tax (PAT) also rose by 23%, reaching ₹451.26 crore compared to ₹367.31 crore the previous year. With a market capitalization of ₹32,012 crore and a P/E ratio of 94.5 as of July 2025, Anthem is positioned as a high-growth stock, though its valuation suggests investors are paying a premium for its potential.
The company’s EBITDA margin of 36.81% in FY25 is among the highest in its peer group, reflecting efficient cost management and a focus on high-margin segments like fee-for-service (FFS) contracts, which account for 86.8% of its revenue. Anthem’s return on equity (ROE) of 18.72% and low debt-to-equity ratio of 0.05 further highlight its financial health, making it a compelling choice for long-term investors.
Industry Position and Growth Drivers
As a leading CRDMO, Anthem Biosciences stands out for its end-to-end services across drug discovery, development, and manufacturing for both small and large molecules. It serves over 550 clients across 44 countries, with 76.75% of its revenue coming from its top 10 customers, primarily in the US, Europe, and Japan. Its expertise in advanced therapies like RNA interference, antibody-drug conjugates, and fermentation-based products like GLP-1 and biosimilars positions it well in high-growth niches.
Anthem’s strategic focus on small and emerging biotech firms, combined with its success-based FFS model (96.76% success rate in FY25), has fostered long-term client relationships. The company is also expanding its fermentation capacity to 182 kL by mid-FY26, which could further boost its revenue. With less than 20% of raw materials sourced from China, Anthem benefits from the “China+1” trend, where global firms seek alternatives to Chinese suppliers.
Risks to Watch Out For
Despite its strengths, Anthem Biosciences faces risks that could impact its share price. Over 70% of its revenue comes from just five customers, making it vulnerable to client loss. Its long cash conversion cycle (222 days in FY25) compared to peers like Syngene (34 days) could strain liquidity. Additionally, the CRDMO market is highly competitive, with over 1,000 global players, which could pressure pricing. Regulatory compliance, operational risks like unit shutdowns, and potential safety issues in its facilities are also concerns investors should monitor.
Share Price Target for 2025
Analyst predictions for Anthem Biosciences’ share price in 2025 vary, reflecting both its growth potential and risks. Based on current GMP trends and analyst reports, the share price is expected to range between ₹472 and ₹749, with a consensus target around ₹713–₹749, implying a potential upside of 25–31% from the IPO price. This optimism is driven by Anthem’s strong financials, global client base, and capacity expansion plans. However, investors should approach with caution due to its high P/E ratio and concentration risks. For long-term investors, Anthem Biosciences appears to be a solid bet, but short-term volatility could arise from market conditions or operational challenges.
In summary, Anthem Biosciences is a promising player in the CRDMO space with strong fundamentals and a bright outlook for 2025. While its high valuation and risks warrant careful consideration, its growth trajectory and industry positioning make it an attractive option for those eyeing the biotech and pharma sectors.